申请人:TAIGEN BIOTECHNOLOGY CO LTD
公开号:WO2021046286A1
公开(公告)日:2021-03-11
A compound of Formula (I) below, or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof: (I), in which Ra, Rb, Rc, Rd, X1, X2, R1-R4, W, Z, and L are defined as in the SUMMARY section. Further disclosed are a method of using the above-described compound, salt, stereoisomer, solvate, or prodrug for treating HBV infection and a pharmaceutical composition containing same.
下面的化合物公式(I),或其药用可接受的盐、立体异构体、溶剂化合物或前药:(I),其中Ra、Rb、Rc、Rd、X1、X2、R1-R4、W、Z和L的定义如摘要部分所述。进一步披露了一种使用上述化合物、盐、立体异构体、溶剂化合物或前药治疗乙型肝炎感染的方法,以及含有同样化合物的药物组合物。